Posts Tagged ‘Actelion’

RSS

June 16th, 2014

Positive Results for New Oral Pulmonary Arterial Hypertension Drug

Actelion has announced positive top-line results for a phase III trial of a new oral drug for the treatment of pulmonary arterial hypertension (PAH). The drug, selexipag, is a first-in-class orally available selective prostacyclin IP receptor agonist. The pivotal, double-blind GRIPHON study was the largest outcome trial ever performed in PAH. A total of 1,156 PAH patients were randomized to selexipag or placebo. […]


March 17th, 2014

Phase 4 Actelion Study Misses Primary Endpoint

Actelion announced today that a phase 4 study with its blockbuster drug bosentan (Tracleer) had failed to meet its primary endpoint. The COMPASS-2 trial was a prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of bosentan on the time to first confirmed event in patients with symptomatic pulmonary arterial hypertension (PAH) already receiving treatment with sildenafil. According to the company, a 17% risk […]


August 28th, 2013

New Drug Found Safe and Effective in Pulmonary Arterial Hypertension — But Does It Save Lives?

Macitentan, a new drug for pulmonary arterial hypertension (PAH), appears to be safe and effective, but it is unclear whether it offers any significant advantages over currently available drugs.  The drug, a dual endothelin-receptor antagonist, is under development from Actelion as an enhanced version of bosentan (Tracleer). The results of a phase 3 trial, SERAPHIN (Study with an Endothelin […]


April 22nd, 2013

Actelion Executive to Head American College of Cardiology

Shalom “Shal” Jacobovitz will be the new chief executive officer of the American College of Cardiology, the ACC announced today. Jacobovitz is currently the president of the U.S. division of Actelion Pharmaceuticals, best known for its pulmonary hypertension drugs. Jacobovitz worked at Hoffmann La Roche, Abbott Canada, Nordic Labs, and Marion Merrill Dow before joining Actelion.  He joins the college […]